Core Viewpoint - The company, Taiankang (301263.SZ), has received approval from the National Medical Products Administration for a seamless Phase II/III clinical trial of CKBA cream for the treatment of rosacea [1] Company Summary - The company's subsidiary, Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. (referred to as "Bochuangyuan"), is responsible for the clinical trial of CKBA [1] - CKBA is a small molecule drug derived from the active ingredient of traditional Chinese medicine, myrrh, which has undergone structural modification and optimization [1] - The drug possesses a novel structure, independent intellectual property rights, a clear mechanism of action, and good safety profile [1] Mechanism of Action - CKBA directly targets and inhibits key enzymes ACC1 and ACC2 involved in the synthesis and metabolism of long-chain fatty acids [1] - It regulates the differentiation of naive CD4+ T cells into Th17 cells, significantly downregulating IL-17A expression and reducing inflammatory cell infiltration [1] - This mechanism helps to improve the typical inflammatory response and erythema associated with rosacea [1]
泰恩康：控股子公司CKBA乳膏玫瑰痤疮适应症获得药物临床试验批准通知书